Skip to content

Women Engaging in Quitting Smoking Together (WE QUIT)

Distress Tolerance Treatment for Weight Concern in Smoking Cessation Among Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02051803
Acronym
WE QUIT
Enrollment
22
Registered
2014-01-31
Start date
2014-03-31
Completion date
2015-06-30
Last updated
2015-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Cessation

Keywords

smoking cessation, women

Brief summary

The long-term goal of this program of research is to develop and disseminate an efficacious intervention for weight concern that will significantly increase smoking cessation rates among women. The overall objective of this project is to develop this intervention and modify it based on piloting and feedback to ensure its feasibility and acceptability. These objectives will be accomplished by pursuing the following specific aim: 1) develop a group-based distress tolerance treatment for weight concern (DT-W) in female smokers and a comparison health education (HE) program and pilot both treatments with three groups of 10 (total N = 30) female weight-concerned smokers (2 DT-W groups, 1 HE group).

Interventions

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Butler Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* female * 18 to 65 years of age * smoke 10 or more cigarettes per day * daily smoker for at least the past year * report motivation to quit smoking in the next month of at least 5 on a 10 point scale * report concern of at least 50 on at least one of two 100 point scales assessing weight concern * able to travel to study location for study appointments

Exclusion criteria

* current use of other smoking cessation or weight loss therapies * current use of other tobacco products at least weekly * current diagnosis of depression * diagnosis or treatment for non-nicotine substance use disorder with substance use during the past 6 months * lifetime diagnosis or treatment of eating disorder, bipolar disorder, schizophrenia, or schizoaffective disorder * current use of psychotropic medication except antidepressants * score above established cut-offs on self-report screening measures of depressive symptomology, eating disorder symptomology, alcohol use disorder, or drug use disorder * current suicidality or homicidality * medical condition that is a contraindication for the use of transdermal nicotine patch * lives at same address as current or past participant

Design outcomes

Primary

MeasureTime frameDescription
Point prevalence abstinence from smoking6 months from smoking quit dateWe will compare the percentage of participants in each treatment group who report abstinence from smoking for the 7 days prior to each follow-up assessment (1-, 3-, and 6-months post-quit date).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026